Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study.
Fanlei HuXiang JiangChunqing GuoYingni LiShixian ChenWei ZhangYan DuPing WangXi ZhengXiangyu FangXin LiJing SongYang XieFei HuangJimeng XueMingxin BaiYuan JiaXu LiuLimin RenXiaoying ZhangJianping GuoHudan PanYin SuHuanfa YiHua YeDaming ZuoJuan LiHuaxiang WuYongfu WangRu LiLiang LiuXiang-Yang WangZhan-Guo LiPublished in: Nature communications (2020)
Early diagnosis is critical to improve outcomes in rheumatoid arthritis (RA), but current diagnostic tools have limited sensitivity. Here we report a large-scale multicenter study involving training and validation cohorts of 3,262 participants. We show that serum levels of soluble scavenger receptor-A (sSR-A) are increased in patients with RA and correlate positively with clinical and immunological features of the disease. This discriminatory capacity of sSR-A is clinically valuable and complements the diagnosis for early stage and seronegative RA. sSR-A also has 15.97% prevalence in undifferentiated arthritis patients. Furthermore, administration of SR-A accelerates the onset of experimental arthritis in mice, whereas inhibition of SR-A ameliorates the disease pathogenesis. Together, these data identify sSR-A as a potential biomarker in diagnosis of RA, and targeting SR-A might be a therapeutic strategy.
Keyphrases
- rheumatoid arthritis
- disease activity
- early stage
- genetic diversity
- ankylosing spondylitis
- interstitial lung disease
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- electronic health record
- risk factors
- big data
- dendritic cells
- metabolic syndrome
- type diabetes
- mouse model
- cancer therapy
- radiation therapy
- machine learning
- high fat diet induced
- artificial intelligence
- skeletal muscle
- idiopathic pulmonary fibrosis